PR Newswire
MILWAUKEE, Jan. 8, 2024
MILWAUKEE, Jan. 8, 2024 /PRNewswire/ -- Ademi LLP is investigating Ambrx (Nasdaq: ANAM) for possible breaches of fiduciary duty and other violations of law in its transaction with Johnson & Johnson.
Click here to learn how to join the https://www.ademilaw.com/case/ambrx-biopharma-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
In the transaction, Ambrx stockholders will receive only $28.00 per share in cash for a total equity value of approximately $2.0 billion, or $1.9 billion net of estimated cash acquired. The transaction agreement unreasonably limits competing transactions for Ambrx by imposing a significant penalty if Ambrx accepts a competing bid. Ambrx insiders will receive substantial benefits as part of change of control arrangements.
We are investigating the conduct of Ambrx's board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
If you own Ambrx common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/ambrx-biopharma-inc.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts
Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-ambrx-biopharma-inc-has-obtained-a-fair-price-in-its-transaction-with-johnson--johnson-302028532.html
SOURCE Ademi LLP
